Acquiring Company
GTCR
Acquired Company
Surmodics
ChicagoEden PrairieFinancial ServicesFinanceVenture CapitalAngel InvestmentManufacturingBiotechnologyHealth CareMedicalMedical DeviceDescription
Surmodics, Inc. (Nasdaq: SRDX) has entered into a definitive agreement to be acquired by GTCR for $43.00 per share in cash, representing an approximate equity value of $627 million. The transaction reflects GTCR's extensive expertise and domain knowledge in the healthcare sector and positions Surmodics to continue delivering compelling benefits for physicians, patients, and customers.
Quick answer
GTCR is acquiring Surmodics for $627 million, announced May 29, 2024. GTCR is based in Chicago, Illinois, United States.
- How much did GTCR pay for Surmodics?
- The reported deal value is $627 million.
- What does GTCR do?
- GTCR is a leading private equity firm focused on investing in growth and could manage companies.
- Where are GTCR and Surmodics based?
- GTCR is based in Chicago, Illinois, United States. Surmodics is based in Eden Prairie, Minnesota, United States.
- Who are the decision-makers at GTCR?
- Fundz holds 1 contact at GTCR. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Financial Services and Finance
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AA Medical completes acquisition of Surgical Product Solutions, forming strategic partnership (July 11, 2024)
- Eli Lilly and Company acquires manufacturing facility from Nexus Pharmaceuticals to expand U.S. capacity (April 22, 2024)
- BD acquires Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to enhance smart connected care solutions, $4.2B (June 3, 2024)
- Pinegrove Capital Partners' Affiliate to Acquire SVB Capital's Investment Platform Business (May 4, 2024)
- Healthcare Holding Schweiz AG completes acquisition of MCM Medsys AG to expand its product portfolio (April 25, 2024)
- Merck completes acquisition of EyeBio to diversify its late-stage pipeline (July 12, 2024)
Who to call at GTCR, and when
When GTCR changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day GTCR raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GTCR, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GTCR. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GTCR makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Surmodics?
Surmodics was acquired by GTCR, based in Chicago. The deal was reported on May 29, 2024. GTCR is a leading private equity firm focused on investing in growth and could manage companies. They specialize in various sectors including financial services and technology. GTCR is privately held and operates in Financial Services.
When did GTCR acquire Surmodics?
GTCR's acquisition of Surmodics was reported on May 29, 2024. Surmodics, Inc. (Nasdaq: SRDX) has entered into a definitive agreement to be acquired by GTCR for $43.00 per share in cash, representing an approximate equity value of $627 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Surmodics do?
Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It is privately held, operating in Manufacturing, and is based in Eden Prairie.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.